AI assistant
Fagron N.V. — Capital/Financing Update 2015
Sep 30, 2015
3949_iss_2015-09-30_49f07daf-63f5-45d5-97dc-3098be1f80b4.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Regulated information Waregem (Belgium)/Rotterdam (Netherlands)1, 30 September 2015
Publication of guarantor list and compliance certificate
Fagron announces today that there are no changes in the Guarantor List in accordance with the Guarantee Declaration dated 12 June 2012 regarding the € 225,000,000 4.75% Bond with maturity date 2 July 2017.
The list of Guarantors, in accordance with Article 10.4 of the Guarantee Declaration, is available at investors.fagron.com.
In accordance with Condition 10 (b) of the Bonds a new Compliance Certificate is published. This Compliance Certificate is available at investors.fagron.com.
For further information Jan Peeters Chief Financial Officer Tel. +31 88 331 12 52 [email protected]
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
Fagron profile
Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.